Development of pharmacologic disease-modifying therapies for potential use in the treatment of achondroplasia has relied on mechanistic approaches that target the FGFR3 pathway directly or the C-natriuretic peptide pathway, which regulates longitudinal bone growth. This evidence concerns the gene FGFR3 and achondroplasia.